MDS Virtual Congress 2021 Archives - Page 102 of 132

Gabapentin-induced severe myoclonus in a patient with impaired renal function

M. Akkari, M. Messelmani, H. Derbali, M. Mansour, A. Riahi, I. Bedoui, J. Zaouali, R. Mrissa (Tunis, Tunisia)
Gait Dysfunction in Blepharospasm

H. Sarva, S. Lons, T. Baumer, C. Klein, H. Jinnah (New York, USA)
Gait impairment as predictor of falls in patients with early Parkinson’s disease

I. Stankovic, V. Markovic, S. Radovanovic, I. Petrovic, N. Dragasevic, M. Svetel, E. Stefanova, V. Kostic (Belgrade, Serbia)
Gait Improvement in Pegzilarginase-treated Patients With Arginase 1 Deficiency: A Blinded Kinematic Analysis

N. Foreman, G. Bubb, E. Bradford (Colleyville, USA)
Gait instability and dynamic Balance Characteristics in Behavioral variant Frontotemporal dementia: A cross sectional study.

V. Ganapathy, S R. S R, S. Bharath (Bengaluru, India)
GALLIC ACID AMELIORATES THE NEUROBEHAVIOURAL DEFICITS INDUCED BY BISPHENOL A (BPA) IN WISTAR RATS

K. Adigun, M. Ehinmowo, A. Adebiyi, O. Adebiyi (Ibadan, Nigeria)
GASTROINTESTINAL SYMPTOMS ARE ASSOCIATED WITH LEFT PREDOMINANT DOPAMINE TRANSPORTER BINDING DEFICIT IN PARKINSON´S DISEASE

K. Murtomäki, T. Mertsalmi, E. Jaakkola, E. Mäkinen, R. Levo, T. Nojonen, M. Eklund, S. Nuuttila, K. Lindholm, E. Pekkonen, J. Joutsa, T. Noponen, T. Ihalainen, V. Kaasinen, F. Scheperjans (Helsinki, Finland)
GBA Mutation Accumulates Higher Alpha-Synuclein in Alpha-Synucleinopathies

T. Eid (London, United Kingdom)
GBA variants in a multi-ethnic Parkinson’s disease (PD) cohort in Malaysia

JL. Lim, K. Lohmann, AH. Tan, YW. Tay, KA. Ibrahim, Z. Abdul Aziz, AS. Mawardi, S. Datuk Puvanarajah, I. Looi, YK. Chia, TT. Lim, P. Bauer, A. Rolfs, C. Klein, A. Ahmad-Annuar, S-Y. Lim (Kuala Lumpur, Malaysia)
Gender bias in patients with Parkinson’s disease undergoing subthalamic stimulation

S. Jost, L. Strobel, A. Rizos, P. Loehrer, K. Ashkan, J. Evans, F. Rosenkranz, M. Barbe, G. Fink, J. Franklin, A. Sauerbier, C. Nimsky, A. Sattari, K. Ray Chaudhuri, A. Antonini, L. Timmermann, P. Martinez-Martin, M. Silverdale, E. Kalbe, V. Visser-Vandewalle, H. Dafsari (Cologne, Germany)
Genetic factors associated with dementia in Parkinson’s disease in the Parkinson’s Incidence Cohorts Collaboration (PICC)

A. Szwedo, I. Dalen, M. Camacho, R. Lawson, D. Bäckström, L. Forsgren, C. Tzoulis, OB. Tysnes, A. Macleod, C. Counsell, C. Williams-Gray, KF. Pedersen, G. Alves, J. Maple-Grødem (Stavanger, Norway)
Genetic features and long-term outcome of Korean patients with Huntington’s disease.

YS. Hwang, SY. Jo, SH. Lee, SJ. Chung (Seoul, Republic of Korea)
Genetic hypokinetic rigid syndrome: Clinical phenotypes from infancy to adolescence in a series of Chilean Patients

D. Munoz, M. Troncoso, V. Naranjo, P. Santander, S. Lara, V. Saez, M. Hidalgo, I. Ruiz (Santiago, Chile)
Genotype-Phenotype Correlations in Niemann-Pick Disease Type C

N. Kresojević, M. Ječmenica Lukić, A. Tomić, I. Petrović, N. Dragašević, M. Svetel, V. Dobričić, M. Janković, I. Novaković, V. Kostić (Belgrade, Serbia)
Genotype-phenotype relations for GBA as a Parkinson’s disease risk factor gene: MDSGene Systematic Review

T. Usnich, M. Rossi, N. Schell, J. Boehm, N. Steffen, S. Petkovic, S. Schaake, R. Alcalay, K. Lohmann, C. Klein (Lübeck, Germany)
Genotypic and phenotypic spectrum of PINK-1 associated parkinsonism in 44 mutation carriers from 11 Tunisian families

G. El Fessi, Z. Saied, F. Nebli, M. Zouari, S. Belal, S. Ben Sassi (Tunis, Tunisia)
Global access to Parkinson’s disease treatment

JLY. Cheong, ZHK. Goh, C. Marras, C. Tanner, M. Kasten, A. Korczyn, L. Chahine, R. Lo, A. Noyce (London, United Kingdom)
Glucocerebrosidase activity does not predict Parkinson’s Disease risk or severity

N. Omer, N. Giladi, T. Gurevich, A. Bar-Shira, M. Gana-Weisz, T. Glinka, O. Goldstein, M. Kestenbaum, J. Cedarbaum, O. Mabrouk, K. Fraser, J. Shrivan, A. Orr-Urtreger, A. Mirelman, A. Thaler (Tel-Aviv, Israel)
Gluten-induced ataxia: a misdiagnosed cause of sporadic ataxia. A case report

R. Zouari, M. Messelmani, M. Mansour, H. Derbali, A. Riahi, I. Bedoui, J. Zaouali, R. Mrissa (Tunis, Tunisia)
GNAO1 related movement disorders: 2 longitudinally-followed cases

CC. Wang, S. Lee (Lebanon, USA)
GP2: training the next generation of Parkinson’s disease genetics researchers – wherever they are in the world

S. Dey, A. Noyce, C. Bale, M. Kuhl, H. Leonard, P. Lewis, S. Stott, S. Adams, A. Martinez-Carrasco, B. Stecher, S. Bandres-Ciga, G. Genetics Program (London, United Kingdom)
GPi DBS for refractory dystonia 4 years after STN DBS on a Parkinson’s Disease patient

B. Meira, A. Santos, C. Reizinho, R. Barbosa, M. Mendonça, P. Bugalho (Lisbon, Portugal)
GPi-DBS for KMT2B-associated dystonia: systematic review and meta-analysis

A. Saini (New Deelhi, India)
Gut bacterial tyrosine decarboxylase as a predictive biomarker to identify Parkinson’s disease patients with motor fluctuations requiring frequent levodopa administration

S. van Kessel, L. Verhagen Metman, G. Sanzo, P. Mcnamara, A. Keshavarzian, S. El Aidy (Groningen, Netherlands)
Gut dysbiosis in Parkinson’s disease with motor complications

K. Takahashi, H. Nishiwaki, M. Ito, K. Iwaoka, K. Yamahara, K. Takahashi, Y. Suzuki, K. Taguchi, Y. Tsuboi, K. Kashihara, M. Hirayama, K. Ohno, T. Maeda (Shiwa, Japan)
Gut microbiota and nutritional profiles of Parkinson’s disease patients.

M. Lubomski, X. Xu, A. Holmes, S. Mueller, J. Yang, C. Sue, R. Davis (St Leonards, Australia)
Gut microbiota in patients with Parkinson’s disease (PD) predicts disease progression better than clinical features

H. Nishiwaki, M. Ito, T. Hamaguchi, T. Maeda, K. Kashihara, Y. Tsuboi, M. Masahisa, M. Hirayama, K. Ohno (Nagoya City, Japan)
Gut, nasal and oral dysbiosis in Parkinson’s disease

S. Jo, W. Kang, YS. Hwang, SH. Lee, SJ. Chung (Seoul, Republic of Korea)